Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Center for Advanced Multi-Omic Characterization of Cancer

Award Number: U24CA271012
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2022
PERIOD OF PERFORMANCE END DATE: 05/31/2027

Group Awards By:

View Award Description

Center for Advanced Multi-Omic Characterization of Cancer - PROJECT SUMMARY The overall objective of the PNNL Proteome Characterization Center (PCC) is to comprehensively characterize human tumor samples provided by the National Cancer Institute (NCI), and to integrate the multi-omic measurements to support improved understanding of the molecular changes that characterize cancer, and do so in the context of clinical outcome. PNNL has participated in the NCI’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) as a PCC for the past ten years, with responsibility for comprehensive proteogenomic characterization of high-grade serous ovarian, colon, and endometrial cancers, and glioblastoma. The planned PNNL PCC will build on those achievements to extend and advance the CPTAC mission of comprehensive proteogenomic characterization of human cancers to additional cancer types, meeting or exceeding CPTAC key expectations or requirements for sample throughput, coverage, sample size, and data quality. Utilizing an advanced analytical platform, PNNL plans to add analysis of both acetylome and ubiquitinome to the phosphoproteome of prospectively collected human tumors, to betters illuminate key biochemical processes related to protein-protein interactions, protein degradation, and signal transduction. We will also complement the core proteome and post-translational modification (PTM)-ome analysis with global metabolome and lipidome analysis, as well as selected data driven spatial or single-cell proteomics analysis. This will provide additional critical insights on potential metabolic vulnerabilities and tumor heterogeneity as well as microenvironment contributions. This multi-omic analysis strategy will also be applied to preclinical samples, such as cell lines, organoids and patient-derived xenografts. We will also develop targeted mass spectrometric assays using input from the CPTAC consortium, and particularly the Proteogenomic Data Analysis Centers (PGDACs), to prioritize targets for further exploring important mechanistic proteomic changes in independent cohort(s). Throughout this work our measurements will benefit from further performance increases (e.g., sensitivity and throughput) based on refining, validating and implementing developments from both PNNL and the other CPTAC Centers. The PNNL PCC will identify promising cancer signatures and signaling networks through proteomic and metabolomic analysis of human biospecimens and relevant preclinical samples for 2-3 cancer types selected by the CPTAC, using state-of-the-art liquid chromatography-tandem mass spectrometry instrumentation, highly multiplexed isobaric mass-tag labeling (TMT 16-plex), and integrated sample workflows, as well as additional advanced metabolomic, spatial and single-cell proteomic planforms, at a throughput of 300 samples per year. We will also explore mechanistically important proteomic changes in human specimens and model systems using cutting-edge targeted proteomic platforms, analytically validated and highly multiplexed targeted assays, and workflows meeting the CPTAC Tier 2 assay guidelines. Two hundred highly specific, multiplexed targeted proteomics assays will be developed and used for measurements in 300 samples each year. The PNNL PCC will accomplish both unbiased and targeted multi-omic characterization of cancers in conjunction with improving the depth, throughput and quality of both unbiased and targeted data generated by implementing and deploying relevant new technologies, such as nanoscale PTM, metabolomic analysis, and single-cell proteomics analysis. The PNNL PCC will work closely with the other PCCs, PGDACs and PTRCs in the CPTAC network on data integration and bioinformatics analysis, as well as translational applications.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	BATTELLE MEMORIAL INSTITUTE	902 BATTELLE BLVD	RICHLAND	WA	99354	BENTON	USA	Cancer Detection and Diagnosis Research	000	4	1/8/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $1,240,013 )
2025	2025	BATTELLE MEMORIAL INSTITUTE	902 BATTELLE BLVD	RICHLAND	WA	99354	BENTON	USA	Cancer Detection and Diagnosis Research	002	4	4/22/2025	NON-COMPETING CONTINUATION	$1,116,069
2025	2025	BATTELLE MEMORIAL INSTITUTE	902 BATTELLE BLVD	RICHLAND	WA	99354	BENTON	USA	Cancer Detection and Diagnosis Research	004	4	9/5/2025	NON-COMPETING CONTINUATION	$0
2025	2025	BATTELLE MEMORIAL INSTITUTE	902 BATTELLE BLVD	RICHLAND	WA	99354	BENTON	USA	Cancer Detection and Diagnosis Research	003	4	6/10/2025	NON-COMPETING CONTINUATION	$123,944
2025	2024	BATTELLE MEMORIAL INSTITUTE	902 BATTELLE BLVD	RICHLAND	WA	99354	BENTON	USA	Cancer Detection and Diagnosis Research	001	3	2/28/2025	NON-COMPETING CONTINUATION	$0
2025	2024	BATTELLE MEMORIAL INSTITUTE	902 BATTELLE BLVD	RICHLAND	WA	99354	BENTON	USA	Cancer Detection and Diagnosis Research	000	3	11/14/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $1,240,013

Issue Date FY: 2024 ( Subtotal = $1,178,071 )
2024	2024	BATTELLE MEMORIAL INSTITUTE	902 BATTELLE BLVD	RICHLAND	WA	99354	BENTON	USA	Cancer Detection and Diagnosis Research	001	3	6/12/2024	NON-COMPETING CONTINUATION	$1,178,071
2024	2023	BATTELLE MEMORIAL INSTITUTE	902 BATTELLE BLVD	RICHLAND	WA	99354	BENTON	USA	Cancer Detection and Diagnosis Research	000	2	12/27/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $1,178,071

Issue Date FY: 2023 ( Subtotal = $1,732,073 )
2023	2023	BATTELLE MEMORIAL INSTITUTE	902 BATTELLE BLVD	RICHLAND	WA	99354	BENTON	USA	Cancer Detection and Diagnosis Research	001	2	6/7/2023	NON-COMPETING CONTINUATION	$1,215,273
2023	2023	BATTELLE MEMORIAL INSTITUTE	902 BATTELLE BLVD	RICHLAND	WA	99354	BENTON	USA	Trans-NIH Research Support	002	2	6/9/2023	SUPPLEMENT FOR EXPANSION	$516,800
2023	2022	BATTELLE MEMORIAL INSTITUTE	902 BATTELLE BLVD	RICHLAND	WA	99354	BENTON	USA	Cancer Detection and Diagnosis Research	000	1	3/10/2023	NEW	$0
														Subtotal = $1,732,073

Issue Date FY: 2022 ( Subtotal = $1,240,013 )
2022	2022	BATTELLE MEMORIAL INSTITUTE	900 BATTELLE BLVD	RICHLAND	WA	99352	BENTON	USA	Cancer Detection and Diagnosis Research	000	1	6/1/2022	NEW	$1,240,013
2022	2022	BATTELLE MEMORIAL INSTITUTE	900 BATTELLE BLVD	RICHLAND	WA	99352	BENTON	USA	Cancer Detection and Diagnosis Research	001	1	6/8/2022	NEW	$0
														Subtotal = $1,240,013

Grand Total All Awards = $5,390,170

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Center for Advanced Multi-Omic Characterization of Cancer

Award Number: U24CA271012

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2022

PERIOD OF PERFORMANCE END DATE: 05/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer